Skip to main content
SpringerLink
Log in

Myelodysplastic Syndromes

  • Chapter
  • First Online:
Practical Lymph Node and Bone Marrow Pathology

Part of the book series: Practical Anatomic Pathology ((PAP))

  • 1558 Accesses

Abstract

Although the diagnosis and classification of most cases of the myelodysplastic syndromes (MDS) is usually accomplished without difficulty, a minority of cases may pose diagnostic problems. In many cases the diagnostic dilemma can be solved by adhering to basic guidelines recommended for evaluation of patients suspected of having MDS, and in particular to the quality of the blood and bone marrow specimens submitted for morphologic, immunophenotypic and genetic studies. In other cases, such as patients who have hypocellular MDS or MDS with fibrosis, the criteria for making a diagnosis may be difficult if not impossible to apply, and in still others the diagnostic uncertainty is because the minimal criteria necessary to establish the diagnosis of MDS are not always clearly stated. In this review, some of these diagnostic problems are addressed and some general guidelines for resolving them are suggested. In addition, data are presented that illustrate that the WHO classification offers a valuable tool in the diagnosis and classification of MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  2. Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk Res. 2012;36(12):1453–8.

    Article  PubMed  Google Scholar 

  3. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184(1–2):16–20.

    Article  CAS  PubMed  Google Scholar 

  4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302.

    Article  CAS  PubMed  Google Scholar 

  5. Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med. 1980;93(2):347–53.

    Article  CAS  PubMed  Google Scholar 

  6. Kraus MD, Bartlett NL, Fleming MD, Dorfman DM. Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Am J Surg Pathol. 1998;22(10):1255–66.

    Article  CAS  PubMed  Google Scholar 

  7. Foucar K, Langdon RM 2nd, Armitage JO, Olson DB, Carroll TJ Jr. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985;56(3):553–61.

    Article  CAS  PubMed  Google Scholar 

  8. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847–52.

    Article  PubMed  Google Scholar 

  9. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263–8.

    Article  CAS  PubMed  Google Scholar 

  10. Linman JW, Bagby C Jr. The preleukemic syndrome: clinical and laboratory features, natural course, and management. Nouv Rev Fr Hematol Blood Cells. 1976;17(1–2):11–31.

    CAS  PubMed  Google Scholar 

  11. Rummens JL, Verfaillie C, Criel A, Hidajat M, Vanhoof A, Van den Berghe H, et al. Elliptocytosis and schistocytosis in myelodysplasia: report of two cases. Acta Haematol. 1986;75(3):174–7.

    Article  CAS  PubMed  Google Scholar 

  12. Doll DC, List AF, Dayhoff DA, Loy TS, Ringenberg QS, Yarbro JW. Acanthocytosis associated with myelodysplasia. J Clin Oncol. 1989;7(10):1569–72.

    Article  CAS  PubMed  Google Scholar 

  13. de Cataldo F, Cairoli R, Baudo F, Pezzetti L, Lo Cunsolo CL, Perutelli P, et al. Abnormalities of cytoskeletal proteins of the red blood cells in myelodysplastic syndromes. Int J Hematol. 1994;59(3):227–9.

    PubMed  Google Scholar 

  14. Hertenstein B, Kurrle E, Redenbacher M, Arnold R, Heimpel H. Pseudoreticulocytosis in a patient with myelodysplasia. Ann Hematol. 1993;67(3):127–8.

    Article  CAS  PubMed  Google Scholar 

  15. Aleem A, Murray JA. Spherocytosis preceding the development of myelodysplasia. Clin Lab Haematol. 2001;23(4):249–51.

    Article  CAS  PubMed  Google Scholar 

  16. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78(2):161–6.

    Article  CAS  PubMed  Google Scholar 

  17. Tulliez M, Testa U, Rochant H, Henri A, Vainchenker W, Touboul J, et al. Reticulocytosis, hypochromia, and microcytosis: an unusual presentation of the preleukemic syndrome. Blood. 1982;59(2):293–9.

    Article  CAS  PubMed  Google Scholar 

  18. Tefferi A, Dingli D, Li CY, Mesa RA. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res. 2006;30(6):677–80.

    Article  CAS  PubMed  Google Scholar 

  19. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005;105(2):443–52.

    Article  CAS  PubMed  Google Scholar 

  20. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.

    Article  CAS  PubMed  Google Scholar 

  21. Head DR, Kopecky K, Bennett JM, Grenier K, Morrison FS, Miller KB, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study. Cancer. 1989;64(11):2199–202.

    Article  CAS  PubMed  Google Scholar 

  22. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712–7.

    Article  PubMed  Google Scholar 

  23. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(1):129–47.

    Article  PubMed  Google Scholar 

  24. Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008;21(11):1394–402.

    Article  PubMed  Google Scholar 

  25. Calvo X, Arenillas L, Luno E, Senent L, Arnan M, Ramos F, et al. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Am J Hematol. 2017;92(7):614–21.

    Article  PubMed  Google Scholar 

  26. Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012;97(10):1459–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol. 1983;55(2):217–27.

    Article  CAS  PubMed  Google Scholar 

  28. Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003;101(9):3386–90.

    Article  CAS  PubMed  Google Scholar 

  29. Fureder W, Schernthaner GH, Ghannadan M, Hauswirth A, Sperr WR, Semper H, et al. Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Investig. 2001;31(10):894–901.

    Article  CAS  Google Scholar 

  30. Shibata K, Watanabe M, Yano H, Matsuzaki M, Funai N, Sano M. Importance of basophilia in haematopoietic disorders. Haematologia (Budap). 1998;29(3):241–53.

    CAS  Google Scholar 

  31. Wimazal F, Baumgartner C, Sonneck K, Zauner C, Geissler P, Schur S, et al. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Investig. 2008;38(6):447–55.

    Article  CAS  Google Scholar 

  32. Goasguen JE, Bennett JM, Bain BJ, Brunning R, Vallespi MT, Tomonaga M, et al. Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2014;38(4):447–53.

    Article  PubMed  Google Scholar 

  33. Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res. 2017;57:78–84.

    Article  PubMed  Google Scholar 

  34. Gallardo R, Kranwinkel RN. Pseudo-Chediak-Higashi anomaly. Am J Clin Pathol. 1985;83(1):127–9.

    Article  CAS  PubMed  Google Scholar 

  35. Langenhuijsen MM. Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol. 1984;58(2):227–30.

    Article  CAS  PubMed  Google Scholar 

  36. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705–14.

    Article  CAS  PubMed  Google Scholar 

  37. Germing U, Platzbecker U, Giagounidis A, Aul C. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Br J Haematol. 2007;138(3):399–400.

    Article  PubMed  Google Scholar 

  38. Widell S, Hast R. Balloon-like platelets in myelodysplastic syndromes – a feature of dysmegakaryopoiesis? Leuk Res. 1987;11(8):747–52.

    Article  CAS  PubMed  Google Scholar 

  39. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood. 2002;99(8):3074–5.

    Article  CAS  PubMed  Google Scholar 

  40. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q-anomaly. Cancer Genet Cytogenet. 1985;17(3):189–255.

    Article  PubMed  Google Scholar 

  41. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4(3):325–45.

    Article  PubMed  Google Scholar 

  42. Thiede T, Engquist L, Billstrom R. Application of megakaryocytic morphology in diagnosing 5q- syndrome. Eur J Haematol. 1988;41(5):434–7.

    Article  CAS  PubMed  Google Scholar 

  43. Podolak-Dawidziak M, Geddes D, Bowen D. Megakaryocytopoiesis in patients with myelodysplastic syndromes (MDS) with and without del(5q). Eur J Haematol. 1990;45(2):115–6.

    Article  CAS  PubMed  Google Scholar 

  44. Goasguen JE, Bennett JM, Bain BJ, Brunning RD, Vallespi MT, Tomonaga M, et al. Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: difficulties in the assessment of dysplasia. Leuk Res. 2016;45:75–81.

    Article  PubMed  Google Scholar 

  45. McCrae T. Acute lymphatic leukaemia, with the report of five cases. Br Med J. 1905;1(2304):404–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Freeman JA. Origin of Auer bodies. Blood. 1966;27(4):499–510.

    Article  CAS  PubMed  Google Scholar 

  47. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma. 1995;17(1–2):79–85.

    Article  CAS  PubMed  Google Scholar 

  48. Willis MS, McKenna RW, Peterson LC, Coad JE, Kroft SH. Low blast count myeloid disorders with Auer rods: a clinicopathologic analysis of 9 cases. Am J Clin Pathol. 2005;124(2):191–8.

    Article  PubMed  Google Scholar 

  49. Yoshida Y, Oguma S, Ohno H. John Auer and Auer rods; controversies revisited. Leuk Res. 2009;33(5):614–6.

    Article  PubMed  Google Scholar 

  50. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27(5):397–404.

    Article  PubMed  Google Scholar 

  51. Seymour JF, Estey EH. The prognostic significance of Auer rods in myelodysplasia. Br J Haematol. 1993;85(1):67–76.

    Google Scholar 

  52. Seigneurin D, Audhuy B. Auer rods in refractory anemia with excess of blasts: presence and significance. Am J Clin Pathol. 1983;80(3):359–62.

    Article  CAS  PubMed  Google Scholar 

  53. Weisdorf DJ, Oken MM, Johnson GJ, Rydell RE. Auer rod positive dysmyelopoietic syndrome. Am J Hematol. 1981;11(4):397–402.

    Article  CAS  PubMed  Google Scholar 

  54. Mertelsmann R, Tzvi Thaler H, To L, Gee TS, McKenzie S, Schauer P, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood. 1980;56(5):773–81.

    Article  CAS  PubMed  Google Scholar 

  55. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86(1):268–76.

    Article  CAS  PubMed  Google Scholar 

  56. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 2000;96(4):1388–92.

    Article  CAS  PubMed  Google Scholar 

  57. Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015;29(1):66–75.

    Article  CAS  PubMed  Google Scholar 

  58. Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011;2011:84–9.

    Article  PubMed  Google Scholar 

  59. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91(3):612–7.

    Article  CAS  PubMed  Google Scholar 

  60. Larson RA, LeBeau MM, Vardiman JW, Rowley JD. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996;104(Suppl 6):1303–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007;127(2):197–205.

    Article  PubMed  Google Scholar 

  62. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, et al. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013;92(10):1335–43.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 2017;35(9):1018–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol. 2017;54(2):105–14.

    Article  PubMed  Google Scholar 

  65. Schaefer EJ, Lindsley RC. Significance of clonal mutations in bone marrow failure and inherited myelodysplastic syndrome/acute myeloid leukemia predisposition syndromes. Hematol Oncol Clin North Am. 2018;32(4):643–55.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Bessis M. Red cell shapes. An illustrated classification and its rationale. Nouv Rev Fr Hematol. 1972;12(6):721–45.

    CAS  PubMed  Google Scholar 

  67. Wang LJ, Glasser L. Spurious dyserythropoiesis. Am J Clin Pathol. 2002;117(1):57–9.

    Article  PubMed  Google Scholar 

  68. Lee SH, van der Weyden C, Mayson E, Desai S. Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia. Int J Lab Hematol. 2013;35(2):163–9.

    Article  PubMed  Google Scholar 

  69. Yang DT, Cook RJ. Spurious elevations of vitamin B12 with pernicious anemia. N Engl J Med. 2012;366(18):1742–3.

    Article  CAS  PubMed  Google Scholar 

  70. Kumar N, Elliott MA, Hoyer JD, Harper CM Jr, Ahlskog JE, Phyliky RL. “Myelodysplasia,” myeloneuropathy, and copper deficiency. Mayo Clin Proc. 2005;80(7):943–6.

    Article  PubMed  Google Scholar 

  71. Haddad AS, Subbiah V, Lichtin AE, Theil KS, Maciejewski JP. Hypocupremia and bone marrow failure. Haematologica. 2008;93(1):e1–5.

    Article  CAS  PubMed  Google Scholar 

  72. Thiele J, Titius BR, Quitmann H, Fischer R, Salzberger B, Dienemann D, et al. Megakaryocytopoiesis in bone marrow biopsies of patients with acquired immunodeficiency syndrome (AIDS). An immunohistochemical and morphometric evaluation with special emphasis on myelodysplastic features and precursor cells. Pathol Res Pract. 1992;188(6):722–8.

    Article  CAS  PubMed  Google Scholar 

  73. Dhurve SA, Dhurve AS. Bone marrow abnormalities in HIV disease. Mediterr J Hematol Infect Dis. 2013;5(1):e2013033.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M, et al. Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med. 2001;40(8):795–801.

    Article  CAS  PubMed  Google Scholar 

  75. Delacretaz F, Perey L, Schmidt PM, Chave JP, Costa J. Histopathology of bone marrow in human immunodeficiency virus infection. Virchows Arch A Pathol Anat Histopathol. 1987;411(6):543–51.

    Article  CAS  PubMed  Google Scholar 

  76. Baurmann H, Schwarz TF, Oertel J, Serke S, Roggendorf M, Huhn D. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. Ann Hematol. 1992;64(1):43–5.

    Article  CAS  PubMed  Google Scholar 

  77. Kerr JR. A review of blood diseases and cytopenias associated with human parvovirus B19 infection. Rev Med Virol. 2015;25(4):224–40.

    Article  PubMed  Google Scholar 

  78. Giannouli S, Kanellopoulou T, Voulgarelis M. Myelodysplasia and autoimmunity. Curr Opin Rheumatol. 2012;24(1):97–102.

    Article  CAS  PubMed  Google Scholar 

  79. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Investig. 2004;34(10):690–700.

    Article  CAS  Google Scholar 

  80. Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology Am Soc Hematol Educ Program. 2012;2012:485–91.

    Article  PubMed  Google Scholar 

  81. DeZern AE, Sekeres MA. The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist. 2014;19(7):735–45.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Devalet B, Mullier F, Chatelain B, Dogne JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95(3):190–8.

    Article  PubMed  Google Scholar 

  83. Ballard HS. The hematological complications of alcoholism. Alcohol Health Res World. 1997;21(1):42–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Yoon JH, Kwak WS, Ahn YS. A brief review of relationship between occupational benzene exposure and hematopoietic cancer. Ann Occup Environ Med. 2018;30:33.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Rezuke WN, Anderson C, Pastuszak WT, Conway SR, Firshein SI. Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. Am J Hematol. 1991;36(4):291–3.

    Article  CAS  PubMed  Google Scholar 

  86. Banerjee R, Halil O, Bain BJ, Cummins D, Banner NR. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation. 2000;70(11):1608–10.

    Article  CAS  PubMed  Google Scholar 

  87. Wang E, Boswell E, Siddiqi I, Lu CM, Sebastian S, Rehder C, et al. Pseudo-Pelger-Huet anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huet anomaly. Am J Clin Pathol. 2011;135(2):291–303.

    Article  PubMed  Google Scholar 

  88. Meyerson HJ, Farhi DC, Rosenthal NS. Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor. Am J Clin Pathol. 1998;109(6):675–81.

    Article  CAS  PubMed  Google Scholar 

  89. Schmitz LL, Litz CE, Brunning RD. Morphologic and quantitative alterations in hematopoietic cells associated with growth factor therapy: review of the literature. Hematol Pathol. 1994;8(3):55–73.

    CAS  PubMed  Google Scholar 

  90. Gauthier-Vasserot A, Thauvin-Robinet C, Bruel AL, Duffourd Y, St-Onge J, Jouan T, et al. Application of whole-exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability. Am J Med Genet A. 2017;173(1):62–71.

    Article  CAS  PubMed  Google Scholar 

  91. Donadieu J, Beaupain B, Fenneteau O, Bellanne-Chantelot C. Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol. 2017;179(4):557–74.

    Article  PubMed  Google Scholar 

  92. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249–56.

    Article  CAS  PubMed  Google Scholar 

  93. Klein C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu Rev Immunol. 2011;29:399–413.

    Article  CAS  PubMed  Google Scholar 

  94. Zeidler C, Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol. 2002;39(2):82–8.

    Article  CAS  PubMed  Google Scholar 

  95. Sera Y, Kawaguchi H, Nakamura K, Sato T, Habara M, Okada S, et al. A comparison of the defective granulopoiesis in childhood cyclic neutropenia and in severe congenital neutropenia. Haematologica. 2005;90(8):1032–41.

    CAS  PubMed  Google Scholar 

  96. Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl. 1956;45(Suppl 105):1–78.

    CAS  PubMed  Google Scholar 

  97. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39(1):86–92.

    Article  CAS  PubMed  Google Scholar 

  98. Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49(5):609–14.

    Article  PubMed  Google Scholar 

  99. Xia J, Bolyard AA, Rodger E, Stein S, Aprikyan AA, Dale DC, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009;147(4):535–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. McDermott DH, De Ravin SS, Jun HS, Liu Q, Priel DA, Noel P, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010;116(15):2793–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Boztug K, Jarvinen PM, Salzer E, Racek T, Monch S, Garncarz W, et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat Genet. 2014;46(9):1021–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Liu JC, Ferreira CG, Yusufzai T. Human CHD2 is a chromatin assembly ATPase regulated by its chromo- and DNA-binding domains. J Biol Chem. 2015;290(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  103. Kao SH, Wu HT. Wu KJ. Ubiquitination by HUWE1 in tumorigenesis and beyond. J Biomed Sci. 2018;25(1):67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Tham E, Lindstrand A, Santani A, Malmgren H, Nesbitt A, Dubbs HA, et al. Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features. Am J Hum Genet. 2015;96(3):507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Arboleda VA, Lee H, Dorrani N, Zadeh N, Willis M, Macmurdo CF, et al. De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. Am J Hum Genet. 2015;96(3):498–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Millan F, Cho MT, Retterer K, Monaghan KG, Bai R, Vitazka P, et al. Whole exome sequencing reveals de novo pathogenic variants in KAT6A as a cause of a neurodevelopmental disorder. Am J Med Genet A. 2016;170(7):1791–8.

    Article  CAS  PubMed  Google Scholar 

  107. Sheikh BN, Yang Y, Schreuder J, Nilsson SK, Bilardi R, Carotta S, et al. MOZ (KAT6A) is essential for the maintenance of classically defined adult hematopoietic stem cells. Blood. 2016;128(19):2307–18.

    Article  CAS  PubMed  Google Scholar 

  108. Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23(5):934–43.

    Article  CAS  PubMed  Google Scholar 

  109. Gambale A, Iolascon A, Andolfo I, Russo R. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Hematol. 2016;9(3):283–96.

    Article  CAS  PubMed  Google Scholar 

  110. Iolascon A, Heimpel H, Wahlin A, Tamary H. Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. Blood. 2013;122(13):2162–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115(8):1519–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. Blood. 2017;129(15):2103–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM. Heterogeneity of GATA2-related myeloid neoplasms. Int J Hematol. 2017;106(2):175–82.

    Article  CAS  PubMed  Google Scholar 

  115. Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, et al. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica. 2011;96(8):1221–5.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol. 1996;94(1):206–9.

    Article  CAS  PubMed  Google Scholar 

  117. Valent P, Jager E, Mitterbauer-Hohendanner G, Mullauer L, Schwarzinger I, Sperr WR, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res. 2011;1(4):531–41.

    PubMed  Google Scholar 

  118. Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483–500.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012;97(5):723–30.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36(1):1–5.

    Article  PubMed  Google Scholar 

  121. Valent P. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology. 2019;86(1):30–38.

    Google Scholar 

  122. Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell. 2018;22(2):157–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol. 2017;54(1):43–50.

    Article  PubMed  Google Scholar 

  124. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18(1):112–21.

    Article  PubMed  Google Scholar 

  126. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Steensma DP. Clinical implications of clonal hematopoiesis. Mayo Clin Proc. 2018;93(8):1122–30.

    Article  PubMed  Google Scholar 

  128. Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  129. Chung SS, Park CY. Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Adv. 2017;1(26):2572–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018;131(5):505–14.

    Article  CAS  PubMed  Google Scholar 

  131. Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology Am Soc Hematol Educ Program. 2015;2015:299–307.

    Article  PubMed  Google Scholar 

  132. Jain M, Tripathi A. ICUS/CCUS/CHIP: basics & beyond. Expert Rev Hematol. 2017;10(10):915–20.

    Article  CAS  PubMed  Google Scholar 

  133. Barcellini W. The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity. Expert Rev Hematol. 2017;10(7):649–57.

    Article  CAS  PubMed  Google Scholar 

  134. Tang G, Medeiros LJ, Wang SA. How I investigate clonal cytogenetic abnormalities of undetermined significance. Int J Lab Hematol. 2018;40(4):385–91.

    Article  CAS  PubMed  Google Scholar 

  135. Braulke F, Platzbecker U, Muller-Thomas C, Gotze K, Germing U, Brummendorf TH, et al. Validation of cytogenetic risk groups according to international prognostic scoring systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica. 2015;100(2):205–13.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820–9.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Valent P, Orazi A, Busche G, Schmitt-Graff A, George TI, Sotlar K, et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010;1(7):483–96.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Pellegrini W, Facchetti F, Marocolo D, Pelizzari AM, Capucci A, Rossi G. Expression of CD34 by megakaryocytes in myelodysplastic syndromes. Haematologica. 2000;85(10):1117–8.

    CAS  PubMed  Google Scholar 

  139. Tang G, Wang SA, Menon M, Dresser K, Woda BA, Hao S. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes. Leuk Res. 2011;35(6):766–70.

    Article  CAS  PubMed  Google Scholar 

  140. Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793–8.

    Article  CAS  PubMed  Google Scholar 

  141. Bento LC, Correia RP, Pitangueiras Mangueira CL, De Souza Barroso R, Rocha FA, Bacal NS, et al. The use of flow cytometry in myelodysplastic syndromes: a review. Front Oncol. 2017;7:270.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica. 2017;102(2):320–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394–403.

    Article  CAS  PubMed  Google Scholar 

  144. Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica. 2017;102(2):308–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, et al. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. Leukemia. 2016;30(3):658–65.

    Article  CAS  PubMed  Google Scholar 

  147. Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, et al. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. Br J Haematol. 2014;167(1):100–9.

    Article  PubMed  Google Scholar 

  148. Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: a study on 804 patients. Cytometry B Clin Cytom. 2015;88(3):154–64.

    Article  PubMed  Google Scholar 

  149. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27; quiz 99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–7.

    Article  CAS  PubMed  Google Scholar 

  151. Bejar R, Greenberg PL. The impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. J Natl Compr Cancer Netw. 2017;15(1):131–5.

    Article  CAS  Google Scholar 

  152. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Jonas BA, Greenberg PL. MDS prognostic scoring systems - past, present, and future. Best Pract Res Clin Haematol. 2015;28(1):3–13.

    Article  PubMed  Google Scholar 

  154. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013;98(6):908–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–82.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691–8.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–52.

    Article  CAS  PubMed  Google Scholar 

  159. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87.

    Article  CAS  PubMed  Google Scholar 

  160. Ornstein MC, Mukherjee S, Sekeres MA. More is better: combination therapies for myelodysplastic syndromes. Best Pract Res Clin Haematol. 2015;28(1):22–31.

    Article  CAS  PubMed  Google Scholar 

  161. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1099–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015;2(1):e12–20.

    Article  PubMed  Google Scholar 

  163. Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.

    Article  CAS  PubMed  Google Scholar 

  165. Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, et al. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Br J Haematol. 2010;148(3):483–4.

    Article  CAS  PubMed  Google Scholar 

  166. Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(9):831–41.

    Article  PubMed  Google Scholar 

  167. Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523(7559):183–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505–11.

    Article  PubMed  Google Scholar 

  169. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011;29(3):303–9.

    Article  CAS  PubMed  Google Scholar 

  170. Aalbers AM, van der Velden VH, Yoshimi A, Fischer A, Noellke P, Zwaan CM, et al. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS. Leukemia. 2014;28(1):189–92.

    Article  CAS  PubMed  Google Scholar 

  171. Vardiman JW. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol. 2003;20(3):154–79.

    Article  PubMed  Google Scholar 

  172. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006:199–204.

    Google Scholar 

  173. Vardiman JW. Myelodysplastic/myeloproliferative diseases. Cancer Treat Res. 2004;121:13–43.

    Article  PubMed  Google Scholar 

  174. Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011;28(4):283–97.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Chicago, Chicago, IL, USA

    Jason X. Cheng & James W. Vardiman

Authors
  1. Jason X. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Vardiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason X. Cheng .

Editor information

Editors and Affiliations

  1. Department of Pathology, Duke University School of Medicine and Duke Health System, Durham, NC, USA

    Endi Wang

  2. Department of Pathology, Duke University School of Medicine and Duke Health System, Durham, NC, USA

    Anand Shreeram Lagoo

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cheng, J.X., Vardiman, J.W. (2020). Myelodysplastic Syndromes. In: Wang, E., Lagoo, A.S. (eds) Practical Lymph Node and Bone Marrow Pathology. Practical Anatomic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-32189-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32189-5_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32188-8

  • Online ISBN: 978-3-030-32189-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation